{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:31:29Z","timestamp":1792276289858,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s15010-023-02167-9","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T06:02:38Z","timestamp":1706853758000},"page":"1113-1123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Ceftazidime-related neurotoxicity in a patient with renal impairment: a case report and literature review"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8871-7385","authenticated-orcid":false,"given":"Dorian","family":"Vanneste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1378-3772","authenticated-orcid":false,"given":"Matthias","family":"Gijsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-5980","authenticated-orcid":false,"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8535-1699","authenticated-orcid":false,"given":"Wim","family":"Van Paesschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1784-8297","authenticated-orcid":false,"given":"Yves","family":"Debaveye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5983-3897","authenticated-orcid":false,"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6342-0676","authenticated-orcid":false,"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"2167_CR1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212527","volume":"7","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, et al. How to manage Pseudomonas aeruginosa infections. Drugs Context. 2018;7: 212527.","journal-title":"Drugs Context"},{"key":"2167_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.37201\/req\/s01.11.2021","volume":"34","author":"M Matesanz","year":"2021","unstructured":"Matesanz M, Mensa J. Ceftazidime-avibactam. Rev Esp Quimioter. 2021;34:38\u201340.","journal-title":"Rev Esp Quimioter"},{"key":"2167_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00003495-198529020-00002","volume":"29","author":"DM Richards","year":"1985","unstructured":"Richards DM, Brogden RN. Ceftazidime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985;29:105\u201361.","journal-title":"Drugs"},{"key":"2167_CR4","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1097\/CCM.0000000000000330","volume":"42","author":"R Ferrer","year":"2014","unstructured":"Ferrer R, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42:1749\u201355.","journal-title":"Crit Care Med"},{"key":"2167_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020;46:1127\u201353.","journal-title":"Intensive Care Med"},{"key":"2167_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"R Guilhaumou","year":"2019","unstructured":"Guilhaumou R, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French society of pharmacology and therapeutics (Societe Francaise de pharmacologie et therapeutique-SFPT) and the French society of anaesthesia and intensive care medicine (Societe Francaise d\u2019anesthesie et reanimation-SFAR). Crit Care. 2019;23:104.","journal-title":"Crit Care"},{"key":"2167_CR7","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2165\/00003088-200544100-00002","volume":"44","author":"F Pea","year":"2005","unstructured":"Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44:1009\u201334.","journal-title":"Clin Pharmacokinet"},{"key":"2167_CR8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/INF.0000000000000778","volume":"34","author":"CJ Arnold","year":"2015","unstructured":"Arnold CJ, et al. Cefepime and ceftazidime safety in hospitalized infants. Pediatr Infect Dis J. 2015;34:964\u20138.","journal-title":"Pediatr Infect Dis J"},{"key":"2167_CR9","first-page":"497","volume":"81","author":"M Beumier","year":"2015","unstructured":"Beumier M, et al. Elevated beta-lactam concentrations associated with neurological deterioration in ICU septic patients. Minerva Anestesiol. 2015;81:497\u2013506.","journal-title":"Minerva Anestesiol"},{"key":"2167_CR10","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1111\/jcpt.13796","volume":"47","author":"X Guo","year":"2022","unstructured":"Guo X, et al. Central nervous system adverse events of ceftazidime\/avibactam: a retrospective study using food and drug administration adverse event reporting system. J Clin Pharm Ther. 2022;47:2369\u201372.","journal-title":"J Clin Pharm Ther"},{"key":"2167_CR11","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/bcp.15612","volume":"89","author":"A Zavrelova","year":"2022","unstructured":"Zavrelova A, et al. Superiority of ceftazidime off-label high-dose regimen in PK\/PD target attainment during treatment of extensively drug-resistant Pseudomonas aeruginosa infections in cancer patients. Br J Clin Pharmacol. 2022;89:1452\u201361.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2167_CR12","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2023.001","volume":"15","author":"A Zavrelova","year":"2023","unstructured":"Zavrelova A, et al. Better outcome of off-label high-dose ceftazidime in hemato-oncological patients with infections caused by extensively drug-resistant Pseudomonas aeruginosa. Mediterr J Hematol Infect Dis. 2023;15(1): e2023001.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2167_CR13","unstructured":"EUCAST, Clinical breakpoints - breakpoints and guidance, C.b. (v13.1), Editor. 2023: https:\/\/www.eucast.org\/clinical_breakpoints."},{"key":"2167_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/archneur.1988.00520330010002","volume":"45","author":"MA Douglas","year":"1988","unstructured":"Douglas MA, Quandt CM, Stanley DA. Ceftazidime-induced encephalopathy in a patient with renal impairment. Arch Neurol. 1988;45:936\u20137.","journal-title":"Arch Neurol"},{"key":"2167_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/j.1875-9114.1991.tb04302.x","volume":"11","author":"RA Slaker","year":"1991","unstructured":"Slaker RA, Danielson B. Neurotoxicity associated with ceftazidime therapy in geriatric patients with renal dysfunction. Pharmacotherapy. 1991;11:351\u20132.","journal-title":"Pharmacotherapy"},{"key":"2167_CR16","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1212\/WNL.41.12.2008","volume":"41","author":"RE Hillsley","year":"1991","unstructured":"Hillsley RE, Massey EW. Truncal asterixis associated with ceftazidime, a third-generation cephalosporin. Neurology. 1991;41:2008.","journal-title":"Neurology"},{"key":"2167_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/jnnp.55.4.333","volume":"55","author":"GD Jackson","year":"1992","unstructured":"Jackson GD, Berkovic SF. Ceftazidime encephalopathy: absence status and toxic hallucinations. J Neurol Neurosurg Psychiatry. 1992;55:333\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2167_CR18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1177\/089686089401400424","volume":"14","author":"WC Lye","year":"1994","unstructured":"Lye WC, Leong SO. Neurotoxicity associated with intraperitoneal ceftazidime therapy in a CAPD patient. Perit Dial Int. 1994;14:408\u20139.","journal-title":"Perit Dial Int"},{"key":"2167_CR19","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1001\/archinte.1994.00420050158014","volume":"154","author":"AD Klion","year":"1994","unstructured":"Klion AD, et al. Ceftazidime-related nonconvulsive status epilepticus. Arch Intern Med. 1994;154:586\u20139.","journal-title":"Arch Intern Med"},{"key":"2167_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0002-9343(01)00767-7","volume":"111","author":"JE Martinez-Rodriguez","year":"2001","unstructured":"Martinez-Rodriguez JE, et al. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med. 2001;111:115\u20139.","journal-title":"Am J Med"},{"key":"2167_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1592\/phco.23.3.369.32100","volume":"23","author":"KM Chow","year":"2003","unstructured":"Chow KM, et al. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy. 2003;23:369\u201373.","journal-title":"Pharmacotherapy"},{"key":"2167_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000077370","volume":"49","author":"A Primavera","year":"2004","unstructured":"Primavera A, Cocito L, Audenino D. Nonconvulsive status epilepticus during cephalosporin therapy. Neuropsychobiology. 2004;49:218\u201322.","journal-title":"Neuropsychobiology"},{"key":"2167_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/15563650600671753","volume":"44","author":"S Vannaprasaht","year":"2006","unstructured":"Vannaprasaht S, et al. Ceftazidime overdose-related nonconvulsive status epilepticus after intraperitoneal instillation. Clin Toxicol (Phila). 2006;44:383\u20136.","journal-title":"Clin Toxicol (Phila)"},{"key":"2167_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/10428190601039755","volume":"48","author":"MG Martin","year":"2007","unstructured":"Martin MG. Encephalopathy with myoclonic jerks resulting from ceftazidime therapy: an under-recognized potential side-effect when treating febrile neutropenia. Leuk Lymphoma. 2007;48:413\u20134.","journal-title":"Leuk Lymphoma"},{"key":"2167_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10072-012-1001-5","volume":"34","author":"UK Misra","year":"2013","unstructured":"Misra UK, et al. Association of antibiotics with status epilepticus. Neurol Sci. 2013;34:327\u201331.","journal-title":"Neurol Sci"},{"key":"2167_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4103\/0971-4065.144426","volume":"25","author":"J Joseph","year":"2015","unstructured":"Joseph J, Vimala A. Ceftazidime-induced myoclonus and encephalopathy in hemodialysis patient. Indian J Nephrol. 2015;25:61\u20132.","journal-title":"Indian J Nephrol"},{"key":"2167_CR27","volume":"10","author":"CY Ong","year":"2018","unstructured":"Ong CY, Qin Y. Myoclonus from antibiotic therapy (ceftazidime-induced neurotoxicity): a case report and review. Cureus. 2018;10: e2250.","journal-title":"Cureus"},{"key":"2167_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jgar.2018.07.010","volume":"15","author":"O Rodr\u00edguez-N\u00fa\u00f1ez","year":"2018","unstructured":"Rodr\u00edguez-N\u00fa\u00f1ez O, et al. Evaluation of ceftazidime\/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. J Glob Antimicrob Resist. 2018;15:136\u20139.","journal-title":"J Glob Antimicrob Resist"},{"key":"2167_CR29","doi-asserted-by":"publisher","first-page":"8936478","DOI":"10.1155\/2019\/8936478","volume":"2019","author":"M Al-Sadawi","year":"2019","unstructured":"Al-Sadawi M, et al. Jerky movement with ceftazidime: a case of ceftazidime-induced neurotoxicity with a review of the literature. Case Rep Med. 2019;2019:8936478.","journal-title":"Case Rep Med"},{"key":"2167_CR30","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1177\/0897190021989931","volume":"35","author":"L Amirouche","year":"2022","unstructured":"Amirouche L, et al. Ceftazidime-induced neurotoxicity in an 80-year-old female with renal dysfunction: a case report. J Pharm Pract. 2022;35:482\u20137.","journal-title":"J Pharm Pract"},{"key":"2167_CR31","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jiac.2022.08.011","volume":"28","author":"M Toda","year":"2022","unstructured":"Toda M, et al. Ceftazidime encephalopathy developed without the elevation of cerebrospinal fluid concentration of ceftazidime: a case report of two cases. J Infect Chemother. 2022;28:1667\u201371.","journal-title":"J Infect Chemother"},{"key":"2167_CR32","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/FTD.0000000000001124","volume":"45","author":"RS Robosa","year":"2023","unstructured":"Robosa RS, et al. Ceftazidime plasma concentrations and neurotoxicity: the importance of therapeutic drug monitoring in patients undergoing different modalities of renal replacement therapy: a grand round. Ther Drug Monit. 2023;45:711\u20133.","journal-title":"Ther Drug Monit"},{"key":"2167_CR33","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.1212\/01.wnl.0000190256.30385.13","volume":"66","author":"S Chan","year":"2006","unstructured":"Chan S, et al. Cephalosporin-induced myoclonus. Neurology. 2006;66:E20.","journal-title":"Neurology"},{"key":"2167_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.4103\/0259-1162.159773","volume":"9","author":"R Haldar","year":"2015","unstructured":"Haldar R, et al. Convulsions following rapid ceftazidime administration for preinduction antibiotic prophylaxis during neurosurgical procedure. Anesth Essays Res. 2015;9:427\u20139.","journal-title":"Anesth Essays Res"},{"key":"2167_CR35","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1177\/0897190015608503","volume":"29","author":"RD Collins","year":"2016","unstructured":"Collins RD, et al. Probable nonconvulsive status epilepticus with the use of high-dose continuous infusion ceftazidime. J Pharm Pract. 2016;29:564\u20138.","journal-title":"J Pharm Pract"},{"key":"2167_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neucli.2020.01.003","volume":"50","author":"K Minh Nguyen","year":"2020","unstructured":"Minh Nguyen K, et al. Focal seizures with a migrating aspect in infants treated with beta-lactam antibiotics: report of two cases. Neurophysiol Clin. 2020;50:81\u20136.","journal-title":"Neurophysiol Clin"},{"key":"2167_CR37","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cmi.2020.11.031","volume":"27","author":"V Pingue","year":"2020","unstructured":"Pingue V, et al. Ceftazidime\/avibactam neurotoxicity in an adult patient with normal renal function. Clin Microbiol Infect. 2020;27:795\u20136.","journal-title":"Clin Microbiol Infect"},{"key":"2167_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 2011;12:77.","journal-title":"BMC Bioinform"},{"key":"2167_CR39","unstructured":"Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury, in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)."},{"key":"2167_CR40","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1212\/WNL.0000000000002455","volume":"86","author":"S Bhattacharyya","year":"2016","unstructured":"Bhattacharyya S, et al. Antibiotic-associated encephalopathy. Neurology. 2016;86:963\u201371.","journal-title":"Neurology"},{"key":"2167_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.seizure.2020.08.012","volume":"81","author":"P Wanleenuwat","year":"2020","unstructured":"Wanleenuwat P, Suntharampillai N, Iwanowski P. Antibiotic-induced epileptic seizures: mechanisms of action and clinical considerations. Seizure. 2020;81:167\u201374.","journal-title":"Seizure"},{"key":"2167_CR42","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3390\/microorganisms9071505","volume":"9","author":"C Roger","year":"2021","unstructured":"Roger C, Louart B. Beta-lactams toxicity in the intensive care unit: an underestimated collateral damage? Microorganisms. 2021;9:1505.","journal-title":"Microorganisms"},{"key":"2167_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000446","volume":"3","author":"EF Barreto","year":"2021","unstructured":"Barreto EF, et al. Setting the beta-lactam therapeutic range for critically ill patients: is there a floor or even a ceiling? Crit Care Explor. 2021;3: e0446.","journal-title":"Crit Care Explor"},{"key":"2167_CR44","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/pds.1761","volume":"18","author":"L Joshua","year":"2009","unstructured":"Joshua L, Devi P, Guido S. Adverse drug reactions in medical intensive care unit of a tertiary care hospital. Pharmacoepidemiol Drug Saf. 2009;18:639\u201345.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2167_CR45","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/jac\/dkz065","volume":"74","author":"PG Cojutti","year":"2019","unstructured":"Cojutti PG, et al. Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa. J Antimicrob Chemother. 2019;74:1648\u201355.","journal-title":"J Antimicrob Chemother"},{"key":"2167_CR46","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/FTD.0b013e3181e60ca6","volume":"32","author":"G Aubert","year":"2010","unstructured":"Aubert G, et al. Prospective determination of serum ceftazidime concentrations in intensive care units. Ther Drug Monit. 2010;32:517\u20139.","journal-title":"Ther Drug Monit"},{"key":"2167_CR47","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/00003088-200039050-00003","volume":"39","author":"I Lutsar","year":"2000","unstructured":"Lutsar I, Friedland IR. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet. 2000;39:335\u201343.","journal-title":"Clin Pharmacokinet"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02167-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-023-02167-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02167-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T14:34:58Z","timestamp":1717166098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-023-02167-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2167"],"URL":"https:\/\/doi.org\/10.1007\/s15010-023-02167-9","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"assertion":[{"value":"31 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval was obtained from the ethics committee of KU Leuven (S68320). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient in accordance with the local ethics committee policy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}